The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

It was an event-filled one for biotech stocks, with the release of a slew of earnings, presentations of clinical trial results and M&A news flow.

Now, here are the upcoming week's key biotech catalysts.

Conferences

• 20th World Congress on Gastroenterology - March 4-5, in Berlin, Germany
• 18th International Conference on Nephrology & Urology - March 4-5, in Berlin
• 24th Annual meet on Surgical Oncology - March 4-5, in Paris, France
• 10th Molecular Immunology & Immunogenetics Congress - March 4-5, in Barcelona, Spain
• Credit Suisse 2019 Global Healthcare Conference – March 5-6, in London
• 32nd Euro Congress on Cancer Science & Therapy - March 7-8, in Barcelona
• 5th International Conference on Mental Health and Human Resilience - March 7-8, 2019 Barcelona

PDUFA Dates

The FDA is likely to rule on Johnson & Johnson JNJ unit Janssen's treatment-resistant drug Esketamine Monday. A FDA panel that reviewed the investigational drug voted 14-2 in favor of its benefit-risk profile.

Clinical Trial Results

Sesen Bio Inc SESN is due to release additional preliminary Phase 3 data for Vicinium, its treatment candidate for non-muscle invasive bladder cancer Monday.

Myokardia Inc MYOK will release additional interim Phase 2 data for its non-obstructive hypertrophic cardiomyopathy candidate Mavacamten Monday.

Earnings

Monday, March 4

• BioCryst Pharmaceuticals, Inc. BCRX (before the market open)
• Sesen Bio (before the market open)
• Myokardia (before the market open)
• Adamas Pharmaceuticals Inc ADMS (after the market close)
• La Jolla Pharmaceutical Company LJPC (after the market close)
• Otonomy Inc OTIC (after the market close)

Tuesday, March 5

• Aerpio Pharmaceuticals Inc ARPO (before the market open)
• Chimerix Inc CMRX (before the market open)
• Obseva SA OBSV (before the market open)
• Neuronetics Inc STIM (before the market open)
• Fate Therapeutics Inc FATE (after the market close)
• BIOLASE Inc BIOL (after the market close)
• Kura Oncology Inc KURA (after the market close)

Wednesday, March 6

• GlycoMimetics IncNASDAQ: (GLYC) (before the market open)
• Jounce Therapeutics Inc JNCE (before the market open)
• OptiNose Inc OPTN (before the market open)
• Xenon Pharmaceuticals Inc XENE (after the market close)
• Assertio Therapeutics Inc ASRT (after the market close)
• CareDx Inc CDNA (after the market close)
• Evoke Pharma Inc EVOK (after the market close)

See Also: Analysts Laud Sarepta's 'Increasingly Active' Gene Therapy Clinical Development

Thursday, March 7

• Orthopediatrics Corp KIDS (before the market open)
• Albireo Pharma Inc ALBO (before the market open)
• ArQule, Inc. ARQL (before the market open)
• Zai Lab Ltd ZLAB (before the market open)
• Syros Pharmaceuticals Inc SYRS (before the market open)
• Celldex Therapeutics, Inc. CLDX (after the market close)
• Kindred Biosciences Inc NKIN (after the market close)
• Pure Bioscience, Inc. Common Stock PURE (after the market close)
• Ocular Therapeutix Inc OCUL (after the market close)
• Aeglea Bio Therapeutics Inc AGLE (after the market close)
• AcelRx Pharmaceuticals Inc ACRX (after the market close)
• Aravive Inc ARAV
• Arbutus Biopharma Corp ABUS (after the market close)
• Geron Corporation GERN (after the market close)
• HTG Molecular Diagnostics Inc HTGM
• Syndax Pharmaceuticals Inc SNDX

Friday, March 8

• Allogene Therapeutics Inc ALLO (before the market open)
• Eloxx Pharmaceuticals Inc ELOX (before the market open)
• PLx Pharma Inc PLXP (before the market open)

IPO

ShockWave Medical, which sells medical devices to treat cardiovascular diseases, is set to offer 5 million shares in an IPO, with an estimated price range of $14-$16. The company expects to list its shares on the Nasdaq under the ticker symbol SWAV.

IPO Quiet Period Expiry

Alector Inc ALEC
Harpoon Therapeutics IncHARP
Gossamer Bio Inc GOSS
ANCHIANO THERAP/S ADR ANCN